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Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81 A45KOmice showed reduced expression of MMPs. This correlates well with
our ﬁnding that stimulation of human OA synovium with WISP1 led to
increased MMP expression. TGF-b signaling via Smad 2/3 is crucial for
maintaining the homeostasis of the cartilage, while signaling via Smad
1/5/8 is associated with chondrocyte hypertrophy. In order to deter-
mine if WISP1 affects TGF-b signaling, we stained WT and WISP1
depleted joints for phosphorylated Smad 2/3. We found that Smad 2/3
signaling was increased in the WISP1 KO mice, suggesting that
increasedWISP1 expression during OA decreases Smad 2/3 signaling. In
addition, recent data showed that WISP1 might not only act as a
downstream target of canonical Wnt signaling, but could also regulate
the accumulation of b-catenin, and positively control canonical Wnt
signaling, further aggravating the OA pathology. To investigate if this
mechanismwas present in experimental OA, we stained our sections for
b-catenin and found thatWISP1 depleted tissues indeed have decreased
levels of b-catenin accumulation in the cartilage.
Conclusions: Overexpression of WISP1 in the synovium and cartilage,
as is found in OA conditions, may play an important role in OA path-
ology via modulation of TGF-b signaling and via a positive feedback
mechanism on canonical Wnt signaling. Because Wnt signaling is both
extremely complex and tightly regulated and can affect many biological
processes, upstream targeting of Wnt signaling is likely to produce
undesired side-effects. Speciﬁc downregulation of WISP1 may more
speciﬁcally target the pathological events that take place during OA
without interfering with normal processes.
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Purpose: Several population studies have found an association between
increased body mass index (BMI), as a measure of obesity, and higher
disc degeneration scores and that the effect of obesity upon back pain is
mediated by greater disc degeneration. However, other pathological
changes to the disc and spinal column, in particular disc herniation and
spinal stenosis, are associated with speciﬁc clinical conditions; whether
these pathological changes are also inﬂuenced by obesity is unclear.
Here we examine the relationships between BMI and MRI measures of
intervertebral disc degeneration (DD), disc herniation (DH) and spinal
stenosis (SS), using a large prospectively recruited patient population.
Methods: Patients were recruited from tertiary spine centres in 4 EU
countries. An experienced radiologist scored T1 and T2 magnetic res-
onance images (MRI) images for DD (Pﬁrrmann grading system), any
DH (size and presence) or any SS (presence and severity). Multivariate
linear and logistic regression analyses were used to model the rela-
tionship between these variables and BMI. Given the comprehensive
data collection, we were able to adjust for both patient (age, gender,
sporting activity, smoking, occupation and comorbidities) and MRI
deﬁned (Modic changes, end plate sclerosis and end plate defects)
confounders.
Results: The analysis included 1684 patients with a mean age of 51
years and BMI of 27.2kg/m2. The relationship between age and DD
(r¼0.66) was considerably stronger than that for BMI and DD (r¼0.17)
(Figure a & b). Lumbar disc degeneration and disc herniation were
both more marked at lower spinal levels with L5/S1 showing the
highest DD and greatest prevalence of DH. In the fully adjusted model,
a 10-year increase in age and a 5kg/m2 increase in BMI were asso-
ciated with a 0.31 unit [CI 0.29,0.34] and 0.04 unit [CI 0.01,0.07]
increase in degeneration, respectively. BMI was not associated with
severe (grade 5) DD (OR 1.06 [CI 0.94,1.20]) or multilevel DD (OR 1.12
[CI 0.96,1.30]). All end plate features were associated with more severe
degeneration. Age (OR 2.60 [CI 2.28,2.96]) and BMI (OR 1.23 [CI
1.06,1.43]) were also positively associated with the presence of
stenosis. BMI was also a positive predictor of multilevel stenosis (OR
1.18 [CI 1.00,1.39]) but not severe stenosis (OR 1.11 [CI 0.92,1.35]). In
contrast, BMI was not a predictor of multilevel herniation (OR 1.14 [CI
0.97,1.35]) but was for severe herniation (OR 1.13 [CI 1.01,1.27]). For DHpresence, age was a negative predictor (OR 0.70 [CI 0.64,0.76]) but BMI
(OR 1.19 [CI 1.07,1.33]) showed a strong positive association. There
were no other signiﬁcant predictors of either DH or SS. When the
upper lumbar spine was considered separately, BMI was the strongest
predictor for disc herniation (OR 1.39 [CI 1.10,1.77]) and spinal stenosis
(OR 1.65 [CI 1.27,2.16]).
Conclusions: An increase in disc degeneration was most strongly
associated with increasing age. Increasing age was also a strong pre-
dictor of spinal stenosis and, after mid-life, a negative predictor for disc
herniation. Higher body mass index was associated with greater disc
degeneration but the small coefﬁcient suggests limited clinical rele-
vance. The upper lumbar discs appear more sensitive to increased BMI,
supporting the upper lumbar spine phenotype described by others.
Abnormal loading in obesity could be a mediator of this. For disc her-
niation and spinal stenosis, BMI is a more clinically meaningful positive
predictor than for disc degeneration. We now need to understand how
obesity predisposes to DH and SS and if weight loss can help prevent
these conditions.
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Purpose: OA and associated joint pain is a major cause of disability,
and there is a high unmet need for effective and safe analgesic
therapies. Substantial pain alleviation has been reported for OA
patients treated with intravenous (IV) infusions of antibodies which
block nerve growth factor (NGF), however an increased drug-related
risk for accelerated OA progression was observed in some patients. As
an alternate strategy for targeting this pathway, we identiﬁed a novel
small molecule compound, GZ389988, as an inhibitor of TrkA, the
high-afﬁnity receptor for NGF. GZ389988 was formulated for intra-
articular (IA) delivery, and its effects on local knee pain were tested in
rats using both a monosodium iodoacetate (MIA) induced model of OA,
as well as an arthritis ﬂare model mediated by streptococcal pepti-
doglycan polysaccharide (PGPS).
Methods: Identiﬁcation of TrkA inhibitor GZ389988: Drug candidate
screening was conducted to select inhibitors of Trk family tyrosine
kinases. Low solubility compounds were evaluated using a cell-based
TrkA assay, and further screened against kinase and safety/liability
panels. Acute cytotoxicity was assessed by neutral red assay for a variety
of cell types, including primary human chondrocytes and synoviocytes
(Articular Engineering). In vivo biocompatibility was tested by IA
injection of GZ389988 into rat knee joints.
Preclinical rat OA model: Unilateral knee OA was initiated by IA
injection of MIA. One week later, diseased (ipsilateral) joints were
treated with a single IA injection of GZ389988 or placebo/vehicle, and
differences in hind-limb weight distribution were measured weekly
for 4 weeks by incapacitance testing. In some cases, GZ389988 was
administered to the contralateral knee instead, to test for the occur-
rence of systemic compound distribution affecting the ipsilateral
joint.
Preclinical rat arthritis ﬂaremodel (Bolder BioPATH): Unilateral primary
knee arthritis was induced by IA injection of PGPS. Two weeks later,
animals received a single IA injection of GZ389988 or placebo/vehicle
into the diseased (ipsilateral) joint. Disease reactivation ﬂares were
triggered by IV administration of PGPS at weeks 1 and 3 following drug
(or placebo) treatment. Gait analysis was conducted by obtaining inked
pawprint impressions from animals which were allowed to ambulate
